| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
103,759,000 |
| Market
Cap: |
971.70(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$8.9 - $24.81 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 10.2 |
| Insider 6 Months : 10.2 |
| Insider 3/6 Months : 20.2 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company developing a pipeline of cancer therapies. Co.'s two primary product candidates are, SNDX-5613 and SNDX-6352 or axatilimab. Co. is developing SNDX-5613, targeting the binding interaction of menin with the mixed lineage leukemia 1 (MLL1) protein for the treatment of MLL-rearranged acute leukemias and nucleophosmin 1 mutant acute myeloid leukemia, as well as axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 receptor. Co. has a collaboration and license agreement with Incyte Corporation for the development and commercialization of axatilimab.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
29,765 |
29,765 |
29,765 |
31,015 |
| Total Buy Value |
$241,896 |
$241,896 |
$241,896 |
$266,933 |
| Total People Bought |
4 |
4 |
4 |
4 |
| Total Buy Transactions |
4 |
4 |
4 |
5 |
| Total Shares Sold |
0 |
29,497 |
29,497 |
218,207 |
| Total Sell Value |
$0 |
$453,737 |
$453,737 |
$4,195,017 |
| Total People Sold |
0 |
3 |
3 |
5 |
| Total Sell Transactions |
0 |
4 |
4 |
7 |
| End Date |
2025-03-30 |
2024-12-27 |
2024-06-28 |
2023-06-29 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Huber Martin H. Jr. |
|
– • – |
2025-05-19 |
4 |
B |
$8.99 |
$44,950 |
D/D |
5,000 |
79,000 |
0.01 |
-3% |
|
| Goldan Keith A. |
Chief Financial Officer |
• – – |
2025-05-19 |
4 |
B |
$0.00 |
$0 |
D/D |
3,000 |
93,746 |
0.01 |
-3% |
|
| Katkin Keith |
|
– • – |
2025-05-19 |
4 |
B |
$9.11 |
$91,120 |
D/D |
10,000 |
100,000 |
0.01 |
-3% |
|
| Botwood Nicholas A.j. |
Head of R&D, CMO |
• – – |
2025-05-16 |
4 |
B |
$9.00 |
$105,826 |
D/D |
11,765 |
35,165 |
0.01 |
-0% |
|
| Botwood Nicholas A.j. |
Head of R&D, CMO |
• – – |
2025-05-12 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
23,400 |
|
-18% |
|
| Metzger Michael A |
Chief Executive Officer |
• • – |
2025-03-14 |
4 |
OE |
$7.20 |
$43,733 |
D/D |
6,074 |
306,195 |
|
- |
|
| Metzger Michael A |
Chief Executive Officer |
• • – |
2025-03-04 |
4 |
AS |
$15.05 |
$117,564 |
D/D |
(7,814) |
300,121 |
|
-37% |
|
| Metzger Michael A |
Chief Executive Officer |
• • – |
2025-03-04 |
4 |
OE |
$7.20 |
$56,261 |
D/D |
7,814 |
307,935 |
|
- |
|
| Gallagher Neil |
President, Head of R&D |
• – – |
2025-02-10 |
4 |
S |
$15.50 |
$71,597 |
D/D |
(4,618) |
85,095 |
|
37% |
|
| Goldan Keith A. |
Chief Financial Officer |
• – – |
2025-02-10 |
4 |
S |
$15.50 |
$58,559 |
D/D |
(3,777) |
90,746 |
|
37% |
|
| Metzger Michael A |
Chief Executive Officer |
• • – |
2025-02-10 |
4 |
S |
$15.50 |
$206,017 |
D/D |
(13,288) |
300,121 |
|
37% |
|
| Rizo Aleksandra |
|
– • – |
2025-02-05 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
25,000 |
|
- |
|
| Huber Martin H. Jr. |
|
– • – |
2025-02-05 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
74,000 |
|
- |
|
| Goldan Keith A. |
Chief Financial Officer |
• – – |
2025-02-05 |
4 |
A |
$0.00 |
$0 |
D/D |
41,900 |
94,523 |
|
- |
|
| Jarrett Jennifer |
|
– • – |
2025-02-05 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
90,000 |
|
- |
|
| Metzger Michael A |
Chief Executive Officer |
• • – |
2025-02-05 |
4 |
A |
$0.00 |
$0 |
D/D |
149,500 |
313,409 |
|
- |
|
| Gallagher Neil |
President, Head of R&D |
• – – |
2025-02-05 |
4 |
A |
$0.00 |
$0 |
D/D |
41,900 |
89,713 |
|
- |
|
| Legault Pierre |
|
– • – |
2025-02-05 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
90,000 |
|
- |
|
| Katkin Keith |
|
– • – |
2025-02-05 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
90,000 |
|
- |
|
| Meury William |
|
– • – |
2025-02-05 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
90,000 |
|
- |
|
| Podlesak Dennis |
|
– • – |
2025-02-05 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
191,763 |
|
- |
|
| Goldan Keith A. |
Chief Financial Officer |
• – – |
2024-06-14 |
4 |
B |
$20.03 |
$25,037 |
D/D |
1,250 |
52,623 |
0.01 |
-6% |
|
| Podlesak Dennis |
|
– • – |
2024-02-07 |
4 |
A |
$0.00 |
$0 |
D/D |
34,000 |
141,763 |
|
- |
|
| Goldan Keith A. |
Chief Financial Officer |
• – – |
2024-02-07 |
4 |
A |
$0.00 |
$0 |
D/D |
46,700 |
51,373 |
|
- |
|
| Katkin Keith |
|
– • – |
2024-02-07 |
4 |
A |
$0.00 |
$0 |
D/D |
17,000 |
65,000 |
|
- |
|
230 Records found
|
|
Page 1 of 10 |
|
|
0.33 (3.6%) 
